"Separation of Entry and Maintenance Is Essential"

Lessons to Be Learned from NASDAQ’s Horizontal Structure

Urgent Need to Diversify Evaluation Criteria

Measures Needed to Support Funding for 'Lower Tiers'

Editor's NoteConcerns are mounting within the bio industry regarding the segment restructuring promoted by the Korea Exchange in an effort to revitalize KOSDAQ. Since novel drug development companies tend to pour vast amounts of research and development (R&D) funds into their businesses without generating revenue or profit, a financial-statement–centric approach to grouping top-tier companies could function as a form of stigma. As track record of technology transfer is raised as a criterion for joining the premium league, some point out that this could have the unintended consequence of encouraging promising domestic biotechs to hastily sell their pipelines at undervalued prices. This article examines the potential impact of the KOSDAQ segment restructuring on novel drug development biotechs, the background behind the policy, and possible measures to address related concerns.

①Concerns About the 'Premium League' Favoring Only Aesthetics-Focused Medical Firms


②Technology Transfer Performance as the Criterion? ...Potential to Accelerate Early Technology Outflow


③What It Takes for Segment Restructuring to Truly 'Support Corporate Growth'


Experts and industry associations agree that, in order to prevent market distortion caused by KOSDAQ's segment restructuring, it is vital to first establish a sophisticated evaluation system that reflects the unique dynamics of the novel drug development industry, instead of enforcing an artificial ranking system based solely on financial statements. As with the approach taken in advanced overseas markets, clear separation between the entry and maintenance standards and preventing segment names from forming a lasting stigma are considered crucial in designing the system.


According to the bio industry and financial investment industry on July 27, the US NASDAQ divides its market into three tiers: the Global Select Market, the Global Market, and the Capital Market. While NASDAQ requires strict financial criteria for initial entry into the top tier, after companies are admitted, ongoing requirements are relaxed. In effect, the threshold for initial entry and the benchmark for continued listing are differentiated.

[The Paradox of the KOSDAQ Promotion and Relegation System] ③ What It Takes for the System to Actually Save Companies View original image

Moreover, NASDAQ does not use hierarchical terms like 'first division' and 'second division' in its tier designations. While it separates companies by grade, it embeds flexibility into both the criteria for downgrading and the names themselves, so that assignment to a certain tier does not become a permanent stigma. This dual-structure embodies the belief that segmenting the market is not the same as hierarchizing it. By separating entry and maintenance thresholds, companies that experience temporary performance issues are not immediately downgraded, and by eschewing overt hierarchical terms, being assigned to a lower tier does not amount to failure in itself.


On the other hand, terms such as 'Select' and 'Standard', which are being discussed in KOSDAQ, are already seen as carrying connotations of superiority and inferiority. While the original term 'Premium' has been changed to 'Select', concerns over fundamental hierarchical classification persist. Lee Seung-kyou, Vice President of the Korea Biotechnology Industry Organization (KoreaBIO), said, "We should avoid vertical segmentation and opt for horizontal distinction," adding, "Rather than splitting into fixed ranks, a flexible structure that allows for continual updates and organic movement between segments is needed."


Even if a top-tier segment is established, a clear separation between entry and maintenance requirements remains a consensus across the industry. The Korea Venture Business Association has also recommended using a separate 'Technology Growth Track' that takes into account commercialization cycles specific to each sector in addition to existing financial statement metrics such as market capitalization, revenue, and operating profit. Since it is difficult to apply standardized rules regarding how to set milestones and who should verify them—these factors varying by sector—the financial authorities, exchange operators, and industry officials need to work together to design detailed criteria.


Particularly for biotechs, there is strong demand to diversify evaluation criteria rather than relying solely on licensing-out (technology transfer) as a one-size-fits-all measure of excellence. Vice President Lee added, "While technology transfer is sometimes inevitable in the domestic novel drug development ecosystem, it should not be made the absolute criterion at stages where new value is being created internally. It is necessary to take a tailored, multi-faceted approach—considering outcomes achieved from directly leading clinical trials, global partnering track records, and qualitative technological assessments by expert committees—so that multiple criteria can be selectively applied."


Market specialists warn that if the policy stops at segmenting the market, and if companies designated in the lower ranks are left to struggle with liquidity crunches, policy failure will be unavoidable unless active liquidity support is put in place for them. They call for practical capital inflow mechanisms—such as a 30 trillion won KOSDAQ revitalization fund, a requirement for pension funds and mutual aid associations to invest in the KOSDAQ Standard segment, and relaxed restrictions on venture capital investment in listed companies—to be established together with the new system.



The CEO of a biotech firm said, "While establishing sophisticated and objective standards for segmenting companies is important, what matters more is ensuring that these criteria do not become a stigma, but instead foster confidence that companies can regain momentum through effort. The KOSDAQ market is meant to support companies' capital raising and growth. The moment it becomes a vehicle for imposing hard quantitative barriers and restricting funding, innovative and technologically advanced companies will inevitably turn away from it." He further remarked, "Whether this restructuring plan becomes a stepping stone for innovative companies on the rise, or an indelible mark that brands them for good, depends entirely on the careful design of an ecosystem-wide solution."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing